A Phase 2 interventional study of rozanolixizumab and Placebo in Fibromyalgia, sponsored by UCB Biopharma SRL. Completed at 7 sites in United Kingdom. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2025-07-01.
Sponsored by UCB Biopharma SRL (part of UCB S.A.) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 31 studies in Fibromyalgia with a site in United Kingdom — 4 open to participants now, 6 under way, none of them phase 3. Fibromyalgia · United Kingdom.
Among the 31 studies in Fibromyalgia with a site in United Kingdom, this one is the 18th largest by enrollment of the 22 interventional ones that give a count, is one of 2 that started in 2022, is one of 5 in phase 2, and was the 23rd registered.
1,244 studies on the registry are indexed under Fibromyalgia; 256 are open to participants now.
Browse Fibromyalgia studies →4 of the 31 studies in Fibromyalgia with a site in United Kingdom are open now. Recruiting first, the newest first:
Oxford Brookes University · Sites in United Kingdom
Ages 18–80 · Healthy volunteers
University of Oxford · Sites in United Kingdom
Ages 18+
University of Nottingham · Sites in United Kingdom
Ages 40+ · Healthy volunteers
King's College London · Sites in United Kingdom
Ages 18+
A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →
Of the 161 Fibromyalgia studies recruiting now, 50 (31%) set no upper age limit and 97 (60%) stop at 75 or younger; 15 take children under 18; 35 take healthy volunteers.
This study: 18 Years to 70 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
31 studies; the count open now beside each. This study's row is marked.
First in 2004; this study’s year is marked. 2 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 63 is close to the median of 60 across 938 interventional studies indexed under Fibromyalgia.
Median enrollment 266 across the 22 interventional studies, 112 across the 9 observational. Of the 24 that completed or were terminated, 10 (42%) have results posted.
This tab as a report to print or save as PDF → With an account.
14 of 31 have an industry lead sponsor. The 10 most frequent:
This study is registered under UCB Biopharma SRL, one of the names counted as UCB S.A.. Under that name alone:
UCB Biopharma SRL is the lead sponsor of 130 studies on the registry; 18 are open to participants now.
Of its 71 completed or terminated interventional studies of FDA-regulated products, 50 (70%) have results posted.
UCB S.A. has 3 studies filed under Fibromyalgia — fewer than ten, so there is no comparison to draw.
1 of the studies in Fibromyalgia with a site in United Kingdom that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07874217Oxford Brookes UniversityWhole-body Cryotherapy in Those With Chronic Fatigue: A Feasibility Study | 2027-01-08 |
Add it to your calendar (.ics) → With an account.
Among the 31 studies in Fibromyalgia with a site in United Kingdom, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of the study is to evaluate efficacy and safety of rozanolixizumab to treat adult study participants with severe fibromyalgia syndrome (FMS).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Diagnostic Criteria) plus the following characteristics during the Screening Period:
Exclusion Criteria:
Study participant
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Study participants on Treatment sequence 1 will receive rozanolixizumab and Placebo during the dosing period at pre-specified timepoints.
Drug: rozanolixizumab · Other: Placebo
Study participants on Treatment sequence 2 will receive rozanolixizumab and Placebo during the dosing period at pre-specified timepoints.
Drug: rozanolixizumab · Other: Placebo
Study participants on Treatment sequence 3 will receive Placebo during the dosing period at pre-specified timepoints.
Other: Placebo
Study participants will receive rozanolixizumab during the dosing periods as pre-defined.
Also known as: UCB7665
Study participants will receive Placebo during the dosing periods as pre-defined.
Also known as: PBO
Brief Pain Inventory Short Form (BPI-SF) Average Interference Score at 12 Weeks of Treatment
The BPI-SF was a self-administered questionnaire used to evaluate the severity of a study participant's pain and the impact of this pain on the study participant's daily functioning. The BPI-SF assesses for the location of pain, pain intensity and functional interference from pain. The 7 BPI-SF interference items included: general activity, mood, walking ability, normal work (including housework), relations with other people, sleep, and enjoyment of life. Each item was rated on a 0 (did not interfere) to 10 (completely interfere) scale with a recall period of 24 hours. The BPI-SF interference score ranges 0-70. Higher scores indicated greater interference.
Time frame: At 12 weeks of treatment
Number of Participants With Treatment-emergent Adverse Events (TEAEs) During the Study
An Adverse Event (AE) is any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of study medication, whether or not considered related to the study medication. A TEAE was defined as any AE with an onset date on or after the first dose of investigational medicinal product (IMP) in Run-In and on or before the earliest of the following: the last date of infusion (including Run-Out) +56 days, final contact date, or death. A TEAE is also defined as any unresolved event already present before administration of treatment that worsens in intensity following exposure to the treatment.
Time frame: From Baseline till end of Safety Follow-up (up to Week 33)
Number of Participants With TEAEs Leading to Withdrawal of IMP
An AE is any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of study medication, whether or not considered related to the study medication. A TEAE was defined as any AE with an onset date on or after the first dose of IMP in Run-In and on or before the earliest of the following: the last date of infusion (including Run-Out) +56 days, final contact date, or death.
Time frame: From Baseline till end of Safety Follow-up (up to Week 33)
Brief Pain Inventory Short Form (BPI-SF) Average Interference Score at 24 Weeks of Treatment
The BPI-SF was a self-administered questionnaire used to evaluate the severity of a study participant's pain and the impact of this pain on the study participant's daily functioning. The BPI-SF assesses for the location of pain, pain intensity and functional interference from pain. The 7 BPI-SF interference items included: general activity, mood, walking ability, normal work (including housework), relations with other people, sleep, and enjoyment of life. Each item was rated on a 0 (did not interfere) to 10 (completely interfere) scale with a recall period of 24 hours. The BPI-SF interference score ranges 0-70. Higher scores indicated greater interference.
Time frame: At 24 weeks of treatment
Revised Fibromyalgia Impact Questionnaire (FIQR) Score at 12 Weeks of Treatment
The Revised Fibromyalgia Impact Questionnaire (FIQR) was a 21-item questionnaire with a recall period of 7 days. The FIQR included 3 domains: activities, overall impact, and symptoms. Each item was based on an 11-point numeric rating scale. The FIQR total score was calculated by taking the sum of the following: Activities domain subtotal divided by 3, overall impact" domain subtotal and symptoms domain subtotal divided by 2. The total score ranged from 0 to 100, with 0 denoting the best possible condition and 100 denoting the worst possible condition. Higher scores indicated more severe impact.
Time frame: At 12 weeks of treatment
Mean 7-day Average Daily Pain Score Assessed With Pain Numeric Rating Scale (NRS) at 12 Weeks of Treatment
The Pain Numeric Rating Scale (NRS) was a scale in which a respondent selected a whole number that best described "How much pain have you experienced on average over the past 24 hours?" The 11-point Pain NRS ranged 0 (no pain) to 10 (pain as bad as you can imagine). Mean pain scores were derived the average of the daily assessment over the past 7 days. The higher score represented worst possible pain.
Time frame: At 12 Weeks of treatment
Mean 7-day Fatigue Score Assessed With Fatigue Numeric Rating Scale at 12 Weeks of Treatment
The Fatigue Numeric Rating Scale (NRS) was a scale in which a respondent selected a whole number that best described "How much fatigue have you experienced on average over the past 24 hours?" The 11-point Fatigue NRS ranged 0 (no fatigue) to 10 (fatigue as bad as you can imagine). Mean fatigue scores were derived the average of the daily assessment over the past 7 days. Higher score represented worst possible fatigue.
Time frame: At 12 weeks of treatment
The study started to enroll participants in December 2022 and concluded in July 2024.
| Milestone | Sequence 1: RLZ 12w + RLZ 12w | Sequence 2: PBO + RLZ 12w | Sequence 3: PBO + PBO |
|---|---|---|---|
| Started | 22 | 20 | 21 |
| Completed | 22 | 20 | 21 |
| Not completed | 0 | 0 | 0 |
| Milestone | Sequence 1: RLZ 12w + RLZ 12w | Sequence 2: PBO + RLZ 12w | Sequence 3: PBO + PBO |
|---|---|---|---|
| Started | 22 | 20 | 21 |
| Completed | 19 | 19 | 20 |
| Not completed | 3 | 1 | 1 |
| Withdrew: Adverse event | 2 | 0 | 1 |
| Withdrew: Lost to follow-up | 1 | 0 | 0 |
| Withdrew: Consent withdrawn by study participant (not due to adverse event) | 0 | 1 | 0 |
| Milestone | Sequence 1: RLZ 12w + RLZ 12w | Sequence 2: PBO + RLZ 12w | Sequence 3: PBO + PBO |
|---|---|---|---|
| Started | 19 | 19 | 20 |
| Completed | 17 | 18 | 20 |
| Not completed | 2 | 1 | 0 |
| Withdrew: Lack of efficacy | 0 | 1 | 0 |
| Withdrew: Consent withdrawn by study participant (not due to adverse event) | 1 | 0 | 0 |
| Withdrew: New work commitments | 1 | 0 | 0 |
| Milestone | Sequence 1: RLZ 12w + RLZ 12w | Sequence 2: PBO + RLZ 12w | Sequence 3: PBO + PBO |
|---|---|---|---|
| Started | 17 | 18 | 20 |
| Completed | 17 | 18 | 20 |
| Not completed | 0 | 0 | 0 |
| Milestone | Sequence 1: RLZ 12w + RLZ 12w | Sequence 2: PBO + RLZ 12w | Sequence 3: PBO + PBO |
|---|---|---|---|
| Started | 22 | 20 | 21 |
| Completed | 22 | 20 | 21 |
| Not completed | 0 | 0 | 0 |
The BPI-SF was a self-administered questionnaire used to evaluate the severity of a study participant's pain and the impact of this pain on the study participant's daily functioning. The BPI-SF assesses for the location of pain, pain intensity and functional interference from pain. The 7 BPI-SF interference items included: general activity, mood, walking ability, normal work (including housework), relations with other people, sleep, and enjoyment of life. Each item was rated on a 0 (did not interfere) to 10 (completely interfere) scale with a recall period of 24 hours. The BPI-SF interference score ranges 0-70. Higher scores indicated greater interference.
| score on a scale | Placebo (PBO) | RLZ 12 Weeks |
|---|---|---|
| Brief Pain Inventory Short Form (BPI-SF) Average Interference Score at 12 Weeks of Treatment | 6.30 (5.59 to 7.01) | 5.76 (5.11 to 6.41) |
An Adverse Event (AE) is any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of study medication, whether or not considered related to the study medication. A TEAE was defined as any AE with an onset date on or after the first dose of investigational medicinal product (IMP) in Run-In and on or before the earliest of the following: the last date of infusion (including Run-Out) +56 days, final contact date, or death. A TEAE is also defined as any unresolved event already present before administration of treatment that worsens in intensity following exposure to the treatment.
| Participants | Run-In-PBO | TP1-RLZ | TP1-PBO | TP2-RLZ/RLZ | TP2-PBO/RLZ | TP2-PBO/PBO | Run-Out and SFU-RLZ/RLZ | Run-Out and SFU-PBO/RLZ | Run-Out and SFU-PBO/PBO |
|---|---|---|---|---|---|---|---|---|---|
| Number of Participants With Treatment-emergent Adverse Events (TEAEs) During the Study | 44 | 22 | 41 | 18 | 19 | 19 | 10 | 12 | 11 |
An AE is any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of study medication, whether or not considered related to the study medication. A TEAE was defined as any AE with an onset date on or after the first dose of IMP in Run-In and on or before the earliest of the following: the last date of infusion (including Run-Out) +56 days, final contact date, or death.
| Participants | Run-In-PBO | TP1-RLZ | TP1-PBO | TP2-RLZ/RLZ | TP2-PBO/RLZ | TP2-PBO/PBO | Run-Out and SFU-RLZ/RLZ | Run-Out and SFU-PBO/RLZ | Run-Out and SFU-PBO/PBO |
|---|---|---|---|---|---|---|---|---|---|
| Number of Participants With TEAEs Leading to Withdrawal of IMP | 0 | 3 | 1 | 0 | 0 | 1 | 0 | 0 | 2 |
The BPI-SF was a self-administered questionnaire used to evaluate the severity of a study participant's pain and the impact of this pain on the study participant's daily functioning. The BPI-SF assesses for the location of pain, pain intensity and functional interference from pain. The 7 BPI-SF interference items included: general activity, mood, walking ability, normal work (including housework), relations with other people, sleep, and enjoyment of life. Each item was rated on a 0 (did not interfere) to 10 (completely interfere) scale with a recall period of 24 hours. The BPI-SF interference score ranges 0-70. Higher scores indicated greater interference.
| score on a scale | Placebo | RLZ 24 Weeks |
|---|---|---|
| Brief Pain Inventory Short Form (BPI-SF) Average Interference Score at 24 Weeks of Treatment | 6.30 (5.59 to 7.01) | 5.79 (4.97 to 6.60) |
The Revised Fibromyalgia Impact Questionnaire (FIQR) was a 21-item questionnaire with a recall period of 7 days. The FIQR included 3 domains: activities, overall impact, and symptoms. Each item was based on an 11-point numeric rating scale. The FIQR total score was calculated by taking the sum of the following: Activities domain subtotal divided by 3, overall impact" domain subtotal and symptoms domain subtotal divided by 2. The total score ranged from 0 to 100, with 0 denoting the best possible condition and 100 denoting the worst possible condition. Higher scores indicated more severe impact.
| score on a scale | Placebo (PBO) | RLZ 12 Weeks |
|---|---|---|
| Revised Fibromyalgia Impact Questionnaire (FIQR) Score at 12 Weeks of Treatment | 70.70 (64.90 to 76.50) | 62.30 (57.32 to 67.28) |
The Pain Numeric Rating Scale (NRS) was a scale in which a respondent selected a whole number that best described "How much pain have you experienced on average over the past 24 hours?" The 11-point Pain NRS ranged 0 (no pain) to 10 (pain as bad as you can imagine). Mean pain scores were derived the average of the daily assessment over the past 7 days. The higher score represented worst possible pain.
| score on a scale | Placebo | RLZ 12 Weeks |
|---|---|---|
| Mean 7-day Average Daily Pain Score Assessed With Pain Numeric Rating Scale (NRS) at 12 Weeks of Treatment | 6.59 (5.96 to 7.21) | 6.63 (6.09 to 7.18) |
The Fatigue Numeric Rating Scale (NRS) was a scale in which a respondent selected a whole number that best described "How much fatigue have you experienced on average over the past 24 hours?" The 11-point Fatigue NRS ranged 0 (no fatigue) to 10 (fatigue as bad as you can imagine). Mean fatigue scores were derived the average of the daily assessment over the past 7 days. Higher score represented worst possible fatigue.
| score on a scale | Placebo (PBO) | RLZ 12 Weeks |
|---|---|---|
| Mean 7-day Fatigue Score Assessed With Fatigue Numeric Rating Scale at 12 Weeks of Treatment | 7.26 (6.66 to 7.86) | 6.98 (6.45 to 7.51) |
Collected over From Baseline till end of Safety Follow-up (up to Week 33). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Run-In-PBO | 0/63 (0%) | 0/63 (0%) | 24/63 (38.1%) |
| TP1-RLZ | 0/22 (0%) | 0/22 (0%) | 21/22 (95.5%) |
| TP1-PBO | 0/41 (0%) | 3/41 (7.3%) | 37/41 (90.2%) |
| TP2-RLZ/RLZ | 0/18 (0%) | 0/18 (0%) | 18/18 (100%) |
| TP2-PBO/RLZ | 0/19 (0%) | 0/19 (0%) | 19/19 (100%) |
| TP2-PBO/PBO | 0/20 (0%) | 0/20 (0%) | 16/20 (80%) |
| Run-Out and SFU-RLZ/RLZ | 0/22 (0%) | 0/22 (0%) | 3/22 (13.6%) |
| Run-Out and SFU-PBO/RLZ | 0/20 (0%) | 1/20 (5%) | 8/20 (40%) |
| Run-Out and SFU-PBO/PBO | 0/21 (0%) | 2/21 (9.5%) | 3/21 (14.3%) |
| Event | Run-In-PBO | TP1-RLZ | TP1-PBO | TP2-RLZ/RLZ | TP2-PBO/RLZ | TP2-PBO/PBO | Run-Out and SFU-RLZ/RLZ | Run-Out and SFU-PBO/RLZ | Run-Out and SFU-PBO/PBO |
|---|---|---|---|---|---|---|---|---|---|
| Pulmonary embolismRespiratory, thoracic and mediastinal disorders | 0/63 | 0/22 | 0/41 | 0/18 | 0/19 | 0/20 | 0/22 | 1/20 | 0/21 |
| HeadacheNervous system disorders | 0/63 | 0/22 | 0/41 | 0/18 | 0/19 | 0/20 | 0/22 | 0/20 | 1/21 |
| Back painMusculoskeletal and connective tissue disorders | 0/63 | 0/22 | 0/41 | 0/18 | 0/19 | 0/20 | 0/22 | 0/20 | 1/21 |
| Respiratory syncytial virus bronchiolitisInfections and infestations | 0/63 | 0/22 | 1/41 | 0/18 | 0/19 | 0/20 | 0/22 | 0/20 | 0/21 |
| Intervertebral disc protrusionMusculoskeletal and connective tissue disorders | 0/63 | 0/22 | 1/41 | 0/18 | 0/19 | 0/20 | 0/22 | 0/20 | 0/21 |
| Neck painMusculoskeletal and connective tissue disorders | 0/63 | 0/22 | 1/41 | 0/18 | 0/19 | 0/20 | 0/22 | 0/20 | 0/21 |
| Event | Run-In-PBO | TP1-RLZ | TP1-PBO | TP2-RLZ/RLZ | TP2-PBO/RLZ | TP2-PBO/PBO | Run-Out and SFU-RLZ/RLZ | Run-Out and SFU-PBO/RLZ | Run-Out and SFU-PBO/PBO |
|---|---|---|---|---|---|---|---|---|---|
| HeadacheNervous system disorders | 11/63 | 9/22 | 17/41 | 4/18 | 7/19 | 3/20 | 0/22 | 4/20 | 0/21 |
| DiarrhoeaGastrointestinal disorders | 4/63 | 3/22 | 3/41 | 1/18 | 7/19 | 1/20 | 0/22 | 0/20 | 0/21 |
| Viral upper respiratory tract infectionInfections and infestations | 0/63 | 2/22 | 2/41 | 1/18 | 1/19 | 6/20 | 0/22 | 2/20 | 0/21 |
| NasopharyngitisInfections and infestations | 0/63 | 5/22 | 6/41 | 4/18 | 2/19 | 2/20 | 0/22 | 0/20 | 0/21 |
| NauseaGastrointestinal disorders | 11/63 | 4/22 | 4/41 | 3/18 | 4/19 | 3/20 | 0/22 | 0/20 | 0/21 |
| Infusion site painGeneral disorders | 4/63 | 0/22 | 5/41 | 0/18 | 2/19 | 4/20 | 0/22 | 0/20 | 0/21 |
| Upper respiratory tract infectionInfections and infestations | 0/63 | 0/22 | 6/41 | 0/18 | 0/19 | 4/20 | 2/22 | 0/20 | 2/21 |
| HypersensitivityImmune system disorders | 0/63 | 4/22 | 0/41 | 1/18 | 1/19 | 0/20 | 0/22 | 0/20 | 0/21 |
| Infusion site erythemaGeneral disorders | 0/63 | 0/22 | 0/41 | 0/18 | 3/19 | 0/20 | 0/22 | 0/20 | 0/21 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 0/63 | 1/22 | 2/41 | 0/18 | 3/19 | 2/20 | 0/22 | 0/20 | 0/21 |
The Randomized Set (RS) included all enrolled participants who were randomized into the study.
| Age, Categorical(Participants) | Sequence 1: RLZ 12w + RLZ 12w | Sequence 2: PBO + RLZ 12w | Sequence 3: PBO + PBO | Total |
|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 21 | 20 | 20 | 61 |
| >=65 years | 1 | 0 | 1 | 2 |
| Age, Continuous(years) | Sequence 1: RLZ 12w + RLZ 12w | Sequence 2: PBO + RLZ 12w | Sequence 3: PBO + PBO | Total |
|---|---|---|---|---|
| Mean | 46.3 ± 9.9 | 47.8 ± 10.7 | 47.3 ± 9.5 | 47.1 ± 9.9 |
| Sex: Female, Male(Participants) | Sequence 1: RLZ 12w + RLZ 12w | Sequence 2: PBO + RLZ 12w | Sequence 3: PBO + PBO | Total |
|---|---|---|---|---|
| Female | 21 | 17 | 17 | 55 |
| Male | 1 | 3 | 4 | 8 |
| Race/Ethnicity, Customized(Participants) | Sequence 1: RLZ 12w + RLZ 12w | Sequence 2: PBO + RLZ 12w | Sequence 3: PBO + PBO | Total |
|---|---|---|---|---|
| Asian | 0 | 0 | 1 | 1 |
| Black or African American | 0 | 1 | 1 | 2 |
| White | 22 | 19 | 19 | 60 |
| Race/Ethnicity, Customized(Participants) | Sequence 1: RLZ 12w + RLZ 12w | Sequence 2: PBO + RLZ 12w | Sequence 3: PBO + PBO | Total |
|---|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 1 | 1 |
| Not Hispanic or Latino | 22 | 20 | 20 | 62 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Data from this trial may be requested by qualified researchers six months after product approval in the US and/or Europe, or global development is discontinued, and 18 months after trial completion. Investigators may request access to anonymized individual patient-level data and redacted trial documents which may include: analysis-ready datasets, study protocol, annotated case report form, statistical analysis plan, dataset specifications, and clinical study report. Prior to use of the data, proposals need to be approved by an independent review panel at www.Vivli.org and a signed data sharing agreement will need to be executed. All documents are available in English only, for a prespecified time, typically 12 months, on a password protected portal. This plan may change if the risk of re-identifying trial participants is determined to be too high after the trial is completed; in this case and to protect participants, individual patient-level data would not be made available.
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: Data from this trial may be requested by qualified researchers six months after product approval in the US and/or Europe or global development is discontinued, and 18 months after trial completion.
Access criteria: Qualified researchers may request access to anonymized IPD and redacted study documents which may include: raw datasets, analysis-ready datasets, study protocol, blank case report form, annotated case report form, statistical analysis plan, dataset specifications, and clinical study report. Prior to use of the data, proposals need to be approved by an independent review panel at www.Vivli.org and a signed data sharing agreement will need to be executed. All documents are available in English only, for a pre-specified time, typically 12 months, on a password protected portal.
Data sharing details ↗ · www.vivli.org
Ran from Dec 2022 to primary completion in May 2024, 17 months.
Results were first posted in Jul 2025, 1 year 1 month after primary completion.
Of 24 phase 2 interventional studies under Fibromyalgia, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 35. This study's 17 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Rozanolixizumab